Biodesix Earnings Call Signals Growth With Caveats

Biodesix, Inc. ((BDSX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Biodesix’s latest earnings call struck an optimistic tone, highlighting accelerating revenue growth, industry-leading margins and its first positive adjusted EBITDA quarter, even as management acknowledged ongoing losses, seasonal volatility and pipeline timing risks. Executives framed 2026 as a year of scaling toward durable profitability, supported by expanded sales coverage and a stronger balance sheet.

Strong Revenue Growth and Upbeat 2026 Guidance

Biodesix reported Q4 revenue of $28.8 million, up 41% year over year, bringing fiscal 2025 revenue to $88.5 million, a 24% increase. For 2026, management guided to $106–$112 million in revenue, implying roughly 23% growth at the midpoint and signaling confidence in sustaining its current trajectory.

Lung Diagnostics Momentum

Lung diagnostics remained the growth engine, with Q4 revenue of $25.1 million up 46% and full-year revenue of $79.2 million up 22%. Test volumes reached 18,000 in Q4 and 62,600 for the year, while primary care orders surged 67% and pulmonology volumes grew 26%, supporting broader penetration.

Industry-Leading Gross Margins and Workflow Gains

Gross margin climbed to 83% in Q4 and 81% for the year, expanding 400 and 300 basis points respectively versus last year. Management expects gross margins to hold near 80% through 2026, driven by favorable volume mix, higher prices per test and lower unit costs from workflow optimization.

First Ever Positive Adjusted EBITDA Quarter

The company delivered its first positive adjusted EBITDA quarter at $0.53 million, a sharp improvement from the prior-year period. Full-year adjusted EBITDA loss narrowed to $17.5 million and net loss improved to $4.0 million in Q4 and $35.3 million for the year, pointing to growing operating leverage.

Commercial Expansion and Salesforce Buildout

Biodesix continued to invest in its commercial footprint, ending Q4 with 97 active sales representatives compared with an average of 65 in Q1. Management plans to add roughly six reps per quarter in 2026, noting that historical performance shows new hires typically cover their costs within about three months.

Partnerships, Pipeline and Evidence Generation

The company highlighted development partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories as strategic validation of its approach. A broad pipeline spanning MRD assays, VeriStrat expansions, an ESR1 test and AI-based digital diagnostics is backed by growing real-world and economic data that aim to support payer acceptance.

Stronger Liquidity Position (Pro Forma)

Biodesix ended the quarter with $19.0 million of unrestricted cash, up 14% sequentially, supplemented by $2.3 million of at-the-market equity raised during the period. Including subsequent ATM proceeds, pro forma cash and equivalents reached $33.7 million, while an amended term loan extended maturity to late 2028, boosting flexibility.

Full-Year Profitability Not Yet Achieved

Despite the milestone of a positive adjusted EBITDA quarter, Biodesix remains loss-making on a full-year basis, with a $17.5 million adjusted EBITDA loss and $35.3 million net loss. Management emphasized that the path to sustained profitability will require continued growth, cost discipline and scaling of the commercial model.

One-Time Collections Partially Boosted Q4 Results

Investors were reminded that about $1.0 million of Q4 revenue came from collections on claims older than one year. Management stressed that its core organic lung diagnostics metrics excluded these one-time collections, suggesting underlying demand growth is more representative of ongoing performance.

Near-Term Seasonality and Weather Headwinds

Looking to early 2026, Biodesix warned of typical first-quarter seasonality, with expected step-downs in volume and average selling price. Recent regional storms and deductible dynamics are also anticipated to weigh on near-term results, though these effects are seen as temporary and already reflected in guidance.

Clinical Study Timing Delays (ALTITUDE)

The company disclosed that enrollment in the ALTITUDE study has been stopped, and remaining patients must be followed before meaningful data are available. Management now expects the earliest substantial readout in 2027, delaying a potential clinical catalyst that could have supported faster guideline and adoption progress.

Rising Operating Costs from Commercial Investment

Operating expenses excluding direct costs rose to $25.8 million in Q4 and $99.7 million for the year, increases of 14% and 10% respectively. SG&A climbed on sales hiring, while R&D spending grew 26% for the year, reflecting parallel investment in both commercial reach and the diagnostics pipeline.

Continued Reliance on Financing Actions

To bridge its scale-up phase, Biodesix continued to tap equity markets via an at-the-market program and renegotiated its term loan. While these actions bolstered pro forma liquidity, the modest $19.0 million of unrestricted cash at quarter end underscores ongoing reliance on external capital until operations fully fund growth.

Uncertainty on Guideline Changes and Reimbursement

Management noted that there were no material updates on guideline or HEDIS changes, with potential adjustments not expected until 2026. The company also highlighted that reimbursement strategy is central to pipeline planning, signaling that timing and coverage decisions could influence the commercialization path of new tests.

Forward-Looking Guidance and Growth Drivers

For 2026, Biodesix is targeting $106–$112 million in revenue and gross margins near 80%, while aiming for continued progress toward sustained adjusted EBITDA positivity. The company is banking on expanding its salesforce, higher revenue per test and growth in development services to offset seasonality and macro noise baked into its guidance range.

Biodesix’s earnings call painted a picture of a diagnostics company transitioning from pure growth to early scale, with strong revenue momentum and margin expansion tempered by ongoing losses and financing needs. For investors, the story now hinges on execution in commercial expansion, disciplined spending and the timing of clinical and reimbursement milestones.